维普中文期刊产品整合服务

A Summary and Evaluation of Current Evidence for Myocardial Infarction with Chinese Medicine

查看全文 作  者:WANG [1]Yue;XIAO [2]Lu;MU [3]Wei;YU Hai-[4]long;ZHANG [5]Shuo;TIAN Gui-[6]hua;SHANG Hong-[7]cai 高影响力作者 机构地区:[1]Department of Chinese Medicine,People's Hospital of the Inner Mongolia Autonomous Region,Hohhot 010017,China;[2]Department of Emergency,The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China;[3]Department of Clinical Pharmacology,The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300150,China;[4]Department of Encephalopathy Rehabilitation,The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China;[5]Department of Integrated Traditional Chinese and Western Medicine,Metabolic Diseases Hospital of Tianjin Medical University,Tianjin 300070,China;[6]Department of Massage Pain,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;[7]Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China高影响力机构 出  处:《Chinese Journal of Integrative Medicine》索引2017年第23卷第12期,共8页高影响力期刊 基  金:Supported by the National Natural Science Foundation of China(No.81430098 and 81603495);the National High Level Talents Special Support Plan of the Organization Department of the Central Committee(No.W02020052) 摘  要:Objective: To provide evidence-based recommendations for clinical application and provoke thoughts for future researchers by conducting a comprehensive summary and evaluation of the current evidence profile for the role of Chinese medicine(CM) in treating myocardial infarction(MI). Methods: Online databases including Pub Med, EMBase, Cochrane Library, Chinese National Knowledge Infrastructure(CNKI), Chinese Biomedical Medicine(CBM), VIP Journal Integration Platform, and Wanfang database were systematically searched for literatures on CM in treating MI. After screening, studies were categorized into 5 types, i.e. systematic review(SR), randomized controlled trial(RCT), observational study, case report and basic research. General information was abstracted, and the quality levels of these studies and their conclusions were summarized and assessed. Results: A total of 452 studies including 10 SRs, 123 RCTs, 47 observational studies, 28 case reports, and 244 basic researches were selected. Clinical studies centered primarily on herbal decoction and mostly were not rigorously performed. High-quality studies were predominantly on Chinese patent medicines(CPMs) such as Danshen Injection(丹参注射液), Shenmai Injection(参麦注射液), Shengmai Injection(生脉注射液) and Qishen Yiqi Dripping Pills(芪参益气滴丸). The most frequently observed pattern of drug combination was decoction plus injection. Results of SRs and clinical studies showed that CM may reduce mortality, decrease risk of complication, reduce myocardial injury, improve cardiac function and inhibit ventricular remodeling. Findings from basic researches also supported the positive role of CM in reducing infarct size and myocardial injury, promoting angiogenesis, preventing ventricular remodeling and improving cardiac function. According to the current evidence body, CM has proven effects in the prevention and treatment of MI. It is also found that the effects of CPMs vary with indications. For instance, Shenmai Injection has been found to be especially effective for reducing the incidence of acute clinical events, while CPMs with qi-nourishing and bloodcirculating properties have been proven to be effective in inhibiting ventricular remodeling. High quality evidence supports the use of CM injection for acute MI and CPM for secondary prevention. Reports on adverse events and other safety outcomes associated with CM for MI are scarce. Conclusions: Sufficient evidence supported the use of CM as an adjuvant to Western medicine for preventing and treating MI. The choice of drug use varies with disease stage and treatment objective. However, the quality of the evidence body remains to be enhanced. 关 键 词:Chinese medicine, myocardialinfarction, clinical EVIDENCE
相关文献

参考文献(35)

引证文献(12)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费